Pharmacological Reversal of Histone Methylation Presensitizes Pancreatic Cancer Cells to Nucleoside Drugs: in Vitro Optimization and Novel Nanoparticle Delivery Studies

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Aug 14

PMID 23940717

Citations 10

Authors

Sau Wai Hung

Hardik Mody

Sean Marrache

Yangzom D Bhutia

Franklin Davis

Jong Hyun Cho

Jason Zastre

Shanta Dhar

Chung K Chu

Rajgopal Govindarajan

Affiliations

Soon will be listed here.

Abstract

We evaluated the potential of an investigational histone methylation reversal agent, 3-deazaneplanocin A (DZNep), in improving the chemosensitivity of pancreatic cancer to nucleoside analogs (i.e., gemcitabine). DZNep brought delayed but selective cytotoxicity to pancreatic cancer cells without affecting normal human pancreatic ductal epithelial (HPDE) cells. Co-exposure of DZNep and gemcitabine induced cytotoxic additivity or synergism in both well- and poorly-differentiated pancreatic cell lines by increased apoptosis. In contrast, DZNep exerted antagonism with gemcitabine against HPDE cells with significant reduction in cytotoxicity compared with the gemcitabine-alone regimen. DZNep marginally depended on purine nucleoside transporters for its cytotoxicity, but the transport dependence was circumvented by acyl derivatization. Drug exposure studies revealed that a short priming with DZNep followed by gemcitabine treatment rather than co-treatment of both agents to produce a maximal chemosensitization response in both gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells. DZNep rapidly and reversibly decreased trimethylation of histone H3 lysine 27 but increased trimethylation of lysine 9 in an EZH2- and JMJD1A/2C-dependent manner, respectively. However, DZNep potentiation of nucleoside analog chemosensitization was found to be temporally coupled to trimethylation changes in lysine 27 and not lysine 9. Polymeric nanoparticles engineered to chronologically release DZNep followed by gemcitabine produced pronounced chemosensitization and dose-lowering effects. Together, our results identify that an optimized DZNep exposure can presensitize pancreatic cancer cells to anticancer nucleoside analogs through the reversal of histone methylation, emphasizing the promising clinical utilities of epigenetic reversal agents in future pancreatic cancer combination therapies.

Citing Articles

Epigenetic Regulation Towards Acquired Drug Resistance in Cancer.

Ketkar M, Dutt S Subcell Biochem. 2022; 100:473-502.

PMID: 36301503 DOI: 10.1007/978-3-031-07634-3_14.

Co-Treatment with the Epigenetic Drug, 3-Deazaneplanocin A (DZNep) and Cisplatin after DZNep Priming Enhances the Response to Platinum-Based Therapy in Chondrosarcomas.

Lhuissier E, Aury-Landas J, Lente M, Boumediene K, Bauge C Cancers (Basel). 2021; 13(18).

PMID: 34572877 PMC: 8472299. DOI: 10.3390/cancers13184648.

Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress.

Surnar B, Shah A, Park M, Kalathil A, Kamran M, Ramirez Jaime R ACS Nano. 2021; 15(10):15741-15753.

PMID: 34355558 PMC: 10134441. DOI: 10.1021/acsnano.0c09553.

EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Kang N, Eccleston M, Clermont P, Latarani M, Male D, Wang Y Epigenomics. 2020; 12(16):1457-1476.

PMID: 32938196 PMC: 7607396. DOI: 10.2217/epi-2020-0186.

Polymer nanoparticle-assisted chemotherapy of pancreatic cancer.

Su T, Yang B, Gao T, Liu T, Li J Ther Adv Med Oncol. 2020; 12:1758835920915978.

PMID: 32426046 PMC: 7222269. DOI: 10.1177/1758835920915978.

References

Ougolkov A, Bilim V, Billadeau D . Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res. 2008; 14(21):6790-6. PMC: 2690708. DOI: 10.1158/1078-0432.CCR-08-1013. View

Wong A, Soo R, Yong W, Innocenti F . Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009; 41(2):77-88. DOI: 10.1080/03602530902741828. View

Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee P . Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007; 21(9):1050-63. PMC: 1855231. DOI: 10.1101/gad.1524107. View

Paproski R, Ng A, Yao S, Graham K, Young J, Cass C . The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol. 2008; 74(5):1372-80. DOI: 10.1124/mol.108.048900. View

Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay N . Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008; 47(9):701-6. PMC: 2580832. DOI: 10.1002/mc.20413. View

Qazi A, Aggarwal S, Steffer C, Bouwman D, Weaver D, Gruber S . Laser capture microdissection of pancreatic ductal adeno-carcinoma cells to analyze EzH2 by Western Blot analysis. Methods Mol Biol. 2011; 755:245-56. DOI: 10.1007/978-1-61779-163-5_20. View

Zhou J, Bi C, Cheong L, Mahara S, Liu S, Tay K . The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood. 2011; 118(10):2830-9. DOI: 10.1182/blood-2010-07-294827. View

Crea F, Paolicchi E, Marquez V, Danesi R . Polycomb genes and cancer: time for clinical application?. Crit Rev Oncol Hematol. 2011; 83(2):184-93. DOI: 10.1016/j.critrevonc.2011.10.007. View

Fujii S, Ito K, Ito Y, Ochiai A . Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem. 2008; 283(25):17324-32. PMC: 2427338. DOI: 10.1074/jbc.M800224200. View

10.

Plunkett W, Huang P, Xu Y, Heinemann V, Grunewald R, Gandhi V . Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995; 22(4 Suppl 11):3-10. View

11.

Crea F, Hurt E, Mathews L, Cabarcas S, Sun L, Marquez V . Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer. 2011; 10:40. PMC: 3100246. DOI: 10.1186/1476-4598-10-40. View

12.

Mallen-St Clair J, Soydaner-Azeloglu R, Lee K, Taylor L, Livanos A, Pylayeva-Gupta Y . EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev. 2012; 26(5):439-44. PMC: 3305982. DOI: 10.1101/gad.181800.111. View

13.

Fujii S, Fukamachi K, Tsuda H, Ito K, Ito Y, Ochiai A . RAS oncogenic signal upregulates EZH2 in pancreatic cancer. Biochem Biophys Res Commun. 2012; 417(3):1074-9. DOI: 10.1016/j.bbrc.2011.12.099. View

14.

Radi M, Adema A, Daft J, Cho J, Hoebe E, Alexander L . In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs. J Med Chem. 2007; 50(9):2249-53. DOI: 10.1021/jm0612923. View

15.

Simon J, Kingston R . Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol. 2009; 10(10):697-708. DOI: 10.1038/nrm2763. View

16.

Toll A, Dasgupta A, Potoczek M, Yeo C, Kleer C, Brody J . Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma. Hum Pathol. 2010; 41(9):1205-9. DOI: 10.1016/j.humpath.2010.03.004. View

17.

Puppe J, Drost R, Liu X, Joosse S, Evers B, Cornelissen-Steijger P . BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 2009; 11(4):R63. PMC: 2750125. DOI: 10.1186/bcr2354. View

18.

Kang N, Jun A, Bhutia Y, Kannan N, Unadkat J, Govindarajan R . Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem. 2010; 285(36):28343-52. PMC: 2934698. DOI: 10.1074/jbc.M110.109199. View

19.

Yang X, Lay F, Han H, Jones P . Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci. 2010; 31(11):536-46. PMC: 2967479. DOI: 10.1016/j.tips.2010.08.001. View

20.

Crea F, Fornaro L, Bocci G, Sun L, Farrar W, Falcone A . EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012; 31(3-4):753-61. DOI: 10.1007/s10555-012-9387-3. View